TY - JOUR
T1 - Biomimetic Strategies to Treat Traumatic Brain Injury by Leveraging Fibrinogen
AU - Brown, Ashley C.
AU - Lavik, Erin
AU - Stabenfeldt, Sarah E.
N1 - Funding Information:
The authors also acknowledge the following funding sources: NIH NIAMS (Grant R21AR071017; A.C.B.), NSF CAREER DMR (Grant 1847488; A.C.B.), NIH NINDS (Grant R56NS100732; E.L.), NIH NICHD (Grant DP2HD084067; S.E.S.), and NSF CAREER CBET (Grant 1454282; S.E.S.).
Funding Information:
Dr. Vimala Bharadwaj and Alisha Kodibagkar are acknowledged for their technical assistance in generating the fibrinogen IHC image. Amanda Witten is acknowledged for creating the graphical abstract figure. The authors also acknowledge the following funding sources: NIH NIAMS (Grant R21AR071017; A.C.B.), NSF CAREER DMR (Grant 1847488; A.C.B.), NIH NINDS (Grant R56NS100732; E.L.), NIH NICHD (Grant DP2HD084067; S.E.S.), and NSF CAREER CBET (Grant 1454282; S.E.S.).
Publisher Copyright:
© 2019 American Chemical Society.
PY - 2019/6/27
Y1 - 2019/6/27
N2 - There were over 27 million new cases of traumatic brain injuries (TBIs) in 2016 across the globe. TBIs are often part of complicated trauma scenarios and may not be diagnosed initially because the primary clinical focus is on stabilizing the patient. Interventions used to stabilize trauma patients may inadvertently impact the outcomes of TBIs. Recently, there has been a strong interest in the trauma community toward administrating fibrinogen-containing solutions intravenously to help stabilize trauma patients. While this interventional shift may benefit general trauma scenarios, fibrinogen is associated with potentially deleterious effects for TBIs. Here, we deconstruct what components of fibrinogen may be beneficial as well as potentially harmful following TBI and extrapolate this to biomimetic approaches to treat bleeding and trauma that may also lead to better outcomes following TBI.
AB - There were over 27 million new cases of traumatic brain injuries (TBIs) in 2016 across the globe. TBIs are often part of complicated trauma scenarios and may not be diagnosed initially because the primary clinical focus is on stabilizing the patient. Interventions used to stabilize trauma patients may inadvertently impact the outcomes of TBIs. Recently, there has been a strong interest in the trauma community toward administrating fibrinogen-containing solutions intravenously to help stabilize trauma patients. While this interventional shift may benefit general trauma scenarios, fibrinogen is associated with potentially deleterious effects for TBIs. Here, we deconstruct what components of fibrinogen may be beneficial as well as potentially harmful following TBI and extrapolate this to biomimetic approaches to treat bleeding and trauma that may also lead to better outcomes following TBI.
UR - http://www.scopus.com/inward/record.url?scp=85070025129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070025129&partnerID=8YFLogxK
U2 - 10.1021/acs.bioconjchem.9b00360
DO - 10.1021/acs.bioconjchem.9b00360
M3 - Review article
C2 - 31246419
AN - SCOPUS:85070025129
SN - 1043-1802
VL - 30
SP - 1951
EP - 1956
JO - Bioconjugate chemistry
JF - Bioconjugate chemistry
IS - 7
ER -